<DOC>
	<DOCNO>NCT01441596</DOCNO>
	<brief_summary>The aim study investigate efficacy safety afatinib alone combination vinorelbine , treatment patient HER2-overexpressing metastatic breast cancer , progressive brain lesion trastuzumab and/or lapatinib base therapy</brief_summary>
	<brief_title>Lux-Breast 3 ; Afatinib Alone Combination With Vinorelbine Patients With Human Epidermal Growth Factor Receptor 2 ( HER2 ) Positive Breast Cancer Suffering From Brain Metastases</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Inclusion criterion : 1. patient HER2 positive breast cancer document central nervous system ( CNS ) recurrence/progression ( image ) HER2 inhibitor ( Trastuzumab and/or Lapatinib ) base therapy ( leptomeningeal carcinomatosis site CNS metastases ) 2. least one measurable progressive lesion brain ( =10 mm T1weighted , gadoliniumenhanced Magnetic Resonance Imaging ) . Measurable non measurable extracranial metastasis allow . 3. previous treatment HER2 inhibitor discontinue prior first study treatment administration ( least 14 day trastuzumab antibody , least 7 day lapatinib ) . 4. previous chemotherapy hormonal therapy ( adjuvant metastatic regimen ) allow , chemotherapy must discontinue least 14 day hormonal therapy least 7 day prior first study treatment administration . 5 . Patients must recover baseline condition Common Terminology Criteria Adverse Events ( CTCAE ) version 3.0 grade = 1 acute CTCAE v. 3.0 grade =2 side effect previous treatment . 6. prior surgery , whole brain radiotherapy stereotactic radiosurgery allow provided unequivocal evidence one new and/or progressive brain metastasis completion whole brain radiotherapy stereotactic radiosurgery . Exclusion criterion : 1 . Prior treatment HER2 tyrosine kinase inhibitor lapatinib 2 . Any current malignancy malignancy diagnose within past five ( 5 ) year ( bilateral primary breast cancer , metastases contralateral breast , nonmelanomatous skin cancer situ cervical cancer ) . 3 . Significant chronic recent acute gastrointestinal disorder diarrhoea major symptom e.g . Crohn 's disease , malabsorption Common Terminology Criteria ( CTC ) grade =2 diarrhoea aetiology .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>